Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Brokerages

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) have been given a consensus rating of "Hold" by the five research firms that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $8.00.

VRCA has been the subject of several research reports. Wall Street Zen raised shares of Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright restated a "neutral" rating on shares of Verrica Pharmaceuticals in a report on Tuesday, April 8th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, May 14th.

Verrica Pharmaceuticals Stock Down 9.8%

NASDAQ VRCA traded down $0.06 during trading hours on Monday, reaching $0.58. The company's stock had a trading volume of 262,581 shares, compared to its average volume of 588,909. Verrica Pharmaceuticals has a 1 year low of $0.38 and a 1 year high of $8.98. The company has a market capitalization of $53.53 million, a price-to-earnings ratio of -0.48 and a beta of 1.75. The firm's 50-day moving average price is $0.54 and its 200-day moving average price is $0.63.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The company had revenue of $3.44 million during the quarter, compared to analysts' expectations of $2.53 million. Equities research analysts anticipate that Verrica Pharmaceuticals will post -1.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Caligan Partners LP purchased a new stake in Verrica Pharmaceuticals during the fourth quarter valued at approximately $5,201,000. Boothbay Fund Management LLC bought a new position in shares of Verrica Pharmaceuticals during the 4th quarter valued at approximately $1,811,000. Geode Capital Management LLC raised its holdings in Verrica Pharmaceuticals by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 477,269 shares of the company's stock valued at $334,000 after buying an additional 21,789 shares during the period. Heights Capital Management Inc. bought a new stake in Verrica Pharmaceuticals in the fourth quarter worth $246,000. Finally, Rhumbline Advisers lifted its position in Verrica Pharmaceuticals by 975.2% in the fourth quarter. Rhumbline Advisers now owns 266,093 shares of the company's stock worth $186,000 after buying an additional 241,344 shares during the last quarter. 42.45% of the stock is owned by institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.